Use when packaging AAAI code, data, multimedia appendices, technical appendices, reproducibility evidence, and post-acceptance artifact releases without violating double-blind or immutable-supplement rules.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Use when positioning an AISTATS submission against AI, machine-learning, statistics, and uncertainty literature, including arXiv preprints, workshop versions, concurrent submissions, prior conference versions, PMLR archival status, and the two-community citation coverage that AISTATS reviewers expect.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
실행 점수 미검증
설치 방법 보기설치하기 전에 에이전트에게 전달되는 지시 내용을 확인할 수 있습니다.
Use this to audit novelty and eligibility. Reopen the current CFP for dual-submission, anonymity, and prior-publication rules before advising authors.
| Literature lane | Typical sources | What AISTATS reviewers check |
|---|---|---|
| ML conferences | NeurIPS, ICML, ICLR, UAI, COLT, prior AISTATS volumes in PMLR | Whether the nearest ML method is compared or explicitly distinguished |
| Statistics journals | Annals of Statistics, JMLR, JASA, Biometrika, EJS | Whether classical estimators and known rates are acknowledged |
| Applied statistical fields | Econometrics, biostatistics, epidemiology | Whether identification and inference assumptions follow standard usage |
A bibliography citing only ML venues tells a statistician reviewer that known statistical results may be getting rediscovered — a recognizable AISTATS reject pattern that no amount of benchmark strength repairs.
Imagine the paper proposes a variance-reduced off-policy evaluation estimator with an asymptotic normality result. Its nearest neighbors: a NeurIPS estimator with no inference guarantee, a JASA semiparametric efficiency bound, and a prior AISTATS paper with a slower rate. The novelty sentence should name all three contrasts — inference where the ML line had none, computational tractability where the statistics line stayed abstract, and a sharper rate than the direct predecessor.
[Eligibility] clear / needs declaration / risky
[Closest literatures] <ML/statistics/application>
[Nearest 3 works] <work -> distinction>
[Archival-overlap risk] <none/issues>
[Novelty sentence] <AISTATS-ready contribution contrast>
아직 리뷰가 없습니다. 사용해 본 소감을 남겨 주세요.
로그인 없이 쓸 수 있습니다. 사용 후기, 질문, 작동하지 않은 환경 등을 편하게 남겨 주세요.
아직 댓글이 없습니다. 첫 댓글을 남겨 보세요.
Use when packaging AAAI code, data, multimedia appendices, technical appendices, reproducibility evidence, and post-acceptance artifact releases without violating double-blind or immutable-supplement rules.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Use when drafting an AAAI author response (rebuttal) under the single short character-limited author-feedback window, the no-URL rule, no-new-results guidance, AI-generated-review handling, and the AAAI two-phase review process where Phase-2 papers receive one feedback round before SPC/AC discussion.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Use when preparing an accepted AAAI paper for camera-ready source submission to AAAI Press, including proceedings page limits, two-column template compliance, copyright transfer, purchased extra technical pages, deanonymization, registration, oral or poster presentation, and final public artifact release.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Use when designing or auditing AAAI experiments for the broad-AI program committee, including baselines, ablations, statistical significance, robustness, human evaluation, AI-for-Social-Impact and alignment/safety evidence, compute and cost reporting, and reproducibility-checklist alignment for Phase-1 survival.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Use when positioning an AAAI paper's novelty against archival work, contemporaneous arXiv or workshop papers, and AAAI/IJCAI/NeurIPS/ICML/ICLR neighbors across the broad AI scope, while staying inside AAAI's dual-submission and AI-as-source policy constraints and writing a related-work section legible to non-specialist reviewers.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Use when strengthening an AAAI paper's reproducibility checklist (placed after references), experimental traceability, seed and hyperparameter reporting, compute and cost disclosure, dataset access and licensing, code/data ZIP readiness, and the claim-to-evidence map that Phase-1 reviewers use to judge rigor across AAAI's broad AI scope.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.